Matches in SemOpenAlex for { <https://semopenalex.org/work/W2546236920> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2546236920 endingPage "409" @default.
- W2546236920 startingPage "409" @default.
- W2546236920 abstract "Cardiovascular (CV) and kidney disease are common and significant complications in people with type 2 diabetes (T2DM). CV disease is the leading cause of death, morbidly and hospitalisations for people with T2DM. Furthermore, diabetic kidney disease is a major risk factor for CV disease and is the main reason why patients need renal replacement therapy. In this perspective, we highlight the results of the recent landmark EMPA-REG OUTCOME trial which has shown that empagliflozin, a member of the sodium-glucose co-transporter 2 (SGLT-2) inhibitor class of glucose lowering medications, reduces death from CV causes, hospitalisation for heart failure and progression to end stage kidney disease in patients with T2DM and established CV disease. The SGLT2 receptor mediates high-capacity glucose uptake in the early proximal tubule, and SGLT2 inhibitors, via their ability to promote glycosuria, have been developed as glucose lowering medications. As well as having a glucose lowering effect, SGLT-2 inhibitors also reduce blood pressure, promote weight loss and reduce uric acid levels. Potential side-effects or concerns related to the use of SGLT-2 inhibitors include increased rates of urinary tract infections, genital tract infections, postural hypotension, diabetic ketoacidosis, acute kidney injury and possible increased rates of fractures. The exact mechanisms that result in empagliflozin's dramatic CV and renal protective effects, with a very favourable safety/tolerability profile, in the EMPA-REG study remain to be fully defined. However, they are most likely distinct from the glucose lowering effects of empagliflozin. CV safety trials involving dapagliflozin and canagliflozin, members of the SGLT-2 class, are under way and the results from these studies will help to answer the question as to whether the cardio-renal benefits of empagliflozin are a class-effect or not. Without doubt, trials to investigate whether SGLT-2 inhibitors have cardio-renal protective effects in patients without diabetes will start soon." @default.
- W2546236920 created "2016-11-04" @default.
- W2546236920 creator A5006069892 @default.
- W2546236920 creator A5036715888 @default.
- W2546236920 creator A5043247231 @default.
- W2546236920 date "2016-10-01" @default.
- W2546236920 modified "2023-10-11" @default.
- W2546236920 title "Cardio-renal protection with empagliflozin" @default.
- W2546236920 cites W1525396932 @default.
- W2546236920 cites W2007374852 @default.
- W2546236920 cites W2019285763 @default.
- W2546236920 cites W2028533363 @default.
- W2546236920 cites W2030192134 @default.
- W2546236920 cites W2083562673 @default.
- W2546236920 cites W2101382476 @default.
- W2546236920 cites W2131411448 @default.
- W2546236920 cites W2139339820 @default.
- W2546236920 cites W2143239235 @default.
- W2546236920 cites W2146264128 @default.
- W2546236920 cites W2150192337 @default.
- W2546236920 cites W2165832533 @default.
- W2546236920 cites W2257723432 @default.
- W2546236920 cites W2273304042 @default.
- W2546236920 cites W2301210108 @default.
- W2546236920 cites W2412800896 @default.
- W2546236920 cites W2416348735 @default.
- W2546236920 cites W2424539745 @default.
- W2546236920 cites W2464122426 @default.
- W2546236920 doi "https://doi.org/10.21037/atm.2016.10.36" @default.
- W2546236920 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5107394" @default.
- W2546236920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27867961" @default.
- W2546236920 hasPublicationYear "2016" @default.
- W2546236920 type Work @default.
- W2546236920 sameAs 2546236920 @default.
- W2546236920 citedByCount "17" @default.
- W2546236920 countsByYear W25462369202017 @default.
- W2546236920 countsByYear W25462369202018 @default.
- W2546236920 countsByYear W25462369202019 @default.
- W2546236920 countsByYear W25462369202021 @default.
- W2546236920 countsByYear W25462369202022 @default.
- W2546236920 crossrefType "journal-article" @default.
- W2546236920 hasAuthorship W2546236920A5006069892 @default.
- W2546236920 hasAuthorship W2546236920A5036715888 @default.
- W2546236920 hasAuthorship W2546236920A5043247231 @default.
- W2546236920 hasBestOaLocation W25462369202 @default.
- W2546236920 hasConcept C126322002 @default.
- W2546236920 hasConcept C126894567 @default.
- W2546236920 hasConcept C134018914 @default.
- W2546236920 hasConcept C197934379 @default.
- W2546236920 hasConcept C2775887513 @default.
- W2546236920 hasConcept C2777180221 @default.
- W2546236920 hasConcept C2777422806 @default.
- W2546236920 hasConcept C2777451236 @default.
- W2546236920 hasConcept C2778375690 @default.
- W2546236920 hasConcept C2778653478 @default.
- W2546236920 hasConcept C2779922275 @default.
- W2546236920 hasConcept C2781214132 @default.
- W2546236920 hasConcept C2781283889 @default.
- W2546236920 hasConcept C555293320 @default.
- W2546236920 hasConcept C71924100 @default.
- W2546236920 hasConceptScore W2546236920C126322002 @default.
- W2546236920 hasConceptScore W2546236920C126894567 @default.
- W2546236920 hasConceptScore W2546236920C134018914 @default.
- W2546236920 hasConceptScore W2546236920C197934379 @default.
- W2546236920 hasConceptScore W2546236920C2775887513 @default.
- W2546236920 hasConceptScore W2546236920C2777180221 @default.
- W2546236920 hasConceptScore W2546236920C2777422806 @default.
- W2546236920 hasConceptScore W2546236920C2777451236 @default.
- W2546236920 hasConceptScore W2546236920C2778375690 @default.
- W2546236920 hasConceptScore W2546236920C2778653478 @default.
- W2546236920 hasConceptScore W2546236920C2779922275 @default.
- W2546236920 hasConceptScore W2546236920C2781214132 @default.
- W2546236920 hasConceptScore W2546236920C2781283889 @default.
- W2546236920 hasConceptScore W2546236920C555293320 @default.
- W2546236920 hasConceptScore W2546236920C71924100 @default.
- W2546236920 hasIssue "20" @default.
- W2546236920 hasLocation W25462369201 @default.
- W2546236920 hasLocation W25462369202 @default.
- W2546236920 hasLocation W25462369203 @default.
- W2546236920 hasLocation W25462369204 @default.
- W2546236920 hasOpenAccess W2546236920 @default.
- W2546236920 hasPrimaryLocation W25462369201 @default.
- W2546236920 hasRelatedWork W2406090055 @default.
- W2546236920 hasRelatedWork W2482323928 @default.
- W2546236920 hasRelatedWork W2546236920 @default.
- W2546236920 hasRelatedWork W2756766507 @default.
- W2546236920 hasRelatedWork W2788574161 @default.
- W2546236920 hasRelatedWork W2883001358 @default.
- W2546236920 hasRelatedWork W2979151493 @default.
- W2546236920 hasRelatedWork W3090980657 @default.
- W2546236920 hasRelatedWork W4289689533 @default.
- W2546236920 hasRelatedWork W4296734013 @default.
- W2546236920 hasVolume "4" @default.
- W2546236920 isParatext "false" @default.
- W2546236920 isRetracted "false" @default.
- W2546236920 magId "2546236920" @default.
- W2546236920 workType "article" @default.